CVC Infections in Hemodialysis: Evidence & Quality Improvement
This paper examines the practice problem of central venous catheter (CVC)-related bloodstream infections in hemodialysis patients. It begins by establishing the clinical significance of vascular access-related infections, which rank as the second leading cause of death and the leading cause of hospitalization among this population. The paper then analyzes existing evidence, drawing on multiple peer-reviewed studies to demonstrate how CVCs substantially elevate infection risk compared to other vascular access types. It further reviews prior mitigation efforts — including clinician education, antimicrobial locks, and CDC guidelines — and explains why these have proven insufficient. Finally, it proposes the use of chlorhexidine-impregnated transparent dressings as a quality improvement intervention, structured within the Plan-Do-Study-Act (PDSA) model.
- Introduction: Overview of CVC infection risk in hemodialysis
- Practice Problem: CVC Use in Hemodialysis: Epidemiology and clinical impact of VRBSI
- Analysis of Existing Evidence: Literature review on CVC infection rates and risks
- Prior Mitigation Efforts and Their Limitations: Why past interventions have fallen short
- Proposed Quality Improvement Process: CHG dressing intervention using PDSA model
- References: APA-formatted sources cited in the paper
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its clinical argument in multiple peer-reviewed sources, building a coherent evidence base before proposing an intervention rather than moving directly to recommendations.
- It clearly distinguishes between the necessity of CVCs for hemodialysis patients and their undesirable side effects, acknowledging clinical complexity rather than offering a simplistic critique.
- The proposed intervention (CHG-transparent dressing within a PDSA framework) follows logically from the gap identified in the evidence review, giving the quality improvement plan clear justification.
Key academic technique demonstrated
This paper demonstrates evidence synthesis in a clinical quality improvement context. Rather than summarizing each source in isolation, the author layers findings from multiple studies to establish cumulative evidence — infection rates, cost burdens, prior failed interventions — before arriving at a targeted, evidence-supported recommendation. This approach mirrors the structure expected in evidence-based practice proposals in nursing and allied health disciplines.
Structure breakdown
The paper follows a four-part structure standard in healthcare quality improvement writing: (1) a brief introduction framing the problem, (2) a focused problem statement with epidemiological context, (3) a literature-based evidence analysis covering CVC risks and prior interventions, and (4) a quality improvement plan with a named implementation model (PDSA). References follow APA style. The paper is concise and purposefully focused, appropriate for an undergraduate or early graduate nursing course.
Introduction
Hemodialysis patients are at high risk of infection due to their impaired immune defenses and the repetitive access of the bloodstream required by various vascular access types. The treatment process itself sometimes worsens patients' conditions — for example, frequent antibiotic administration generates antimicrobial resistance and multidrug-resistant organisms. Central venous catheters (CVCs) are among the most commonly used vascular access types. While CVCs are intended to enhance the health and wellbeing of hemodialysis patients, they simultaneously elevate the risk of hospital-acquired infections. This paper provides a brief overview of the practice problem, analyzes existing evidence on this issue, and describes the quality improvement process and quality model that will be used to address it.
Practice Problem: CVC Use in Hemodialysis
The lifeline for patients undergoing long-term hemodialysis is a well-functioning vascular access. This is primarily because hemodialysis patients face a significantly elevated risk of developing vascular access-related bloodstream infections (VRBSI), which can generate severe complications. According to Thompson et al. (2017), infection is regarded as the second leading cause of death among hemodialysis patients and the leading cause of hospitalization. Similarly, Nguyen et al. (2017) note that infections in hemodialysis patients increase hospitalization, mortality, the need for antimicrobials, and healthcare costs. Nguyen et al. (2017) further state that hemodialysis patients are at high risk of infection due to their impaired immune defenses and the repetitive access of the bloodstream through vascular access sites and types such as CVCs.
Over the past 25 years, numerous efforts have been undertaken to reduce the number of bloodstream infections caused by CVC use in hemodialysis and end-stage renal disease patients. These efforts have proven relatively ineffective: the use of CVCs for hemodialysis patients continues to be a major contributor to high bloodstream infection rates, increased healthcare costs, mortality, and morbidity (Hymes et al., 2017). Even though CVCs remain unavoidable for hemodialysis patients who need immediate dialysis access, they continue to produce undesirable side effects by increasing infection risk. These side effects constitute a major practice problem in hemodialysis care settings.
Analysis of Existing Evidence
CVC infections have attracted considerable attention in the existing literature, as they represent a serious and largely avoidable consequence of using central venous catheters in hemodialysis care. Researchers have examined various aspects of this issue with the aim of generating evidence that would promote practice change.
Gahlot et al. (2014) note that intravascular catheters such as CVCs are critical in modern clinical practice for providing care to hemodialysis and end-stage renal disease patients. These catheters are inserted in critically ill patients to facilitate the administration of medication, fluids, nutritional solutions, and blood products, as well as hemodynamic monitoring. While CVCs are integral to the care of critically ill patients, they pose a high risk of device-related infections. Compared to other types of catheters and medical devices, CVCs are major contributors to mortality and morbidity. Prospective studies indicate that the majority of bloodstream infections among hemodialysis patients are associated with CVCs, with the relative risk for bloodstream infection estimated to be approximately 64 times higher than with peripheral venous catheters (Gahlot et al., 2014).
Saxena, Panhotra, and Al-Mulhim (2005) state that hemodialysis patients are at high risk of VRBSI, which contribute to severe complications. Severe VRBSI are most often associated with central venous catheters rather than arteriovenous fistulas. These researchers contend that CVCs remain unavoidable for critically ill patients in need of immediate dialysis access, a reality linked to the unpredictable course of chronic renal disease. For hemodialysis patients, CVCs help maintain a well-functioning vascular access; however, these patients are affected by dialysis access-related infections and subsequent hospitalizations that compromise their overall wellbeing. CVC infections among hemodialysis patients increase healthcare costs, mortality, morbidity, the need for antimicrobials, and rates of hospitalization (Nguyen et al., 2017; Gahlot et al., 2014; Thompson et al., 2017; Saxena, Panhotra & Al-Mulhim, 2005).
Apata et al. (2017) argue that the use of chlorhexidine-impregnated transparent dressings as part of CVC maintenance helps reduce CVC-related infections among hemodialysis patients. Such dressings lower infection rates by allowing ongoing antimicrobial exposure and easy visibility of the catheter insertion site. The use of chlorhexidine-impregnated transparent dressings has been found to be more effective in reducing CVC infections than adhesive dry gauze dressings. Therefore, existing evidence-based practice suggests that CVC infections among hemodialysis patients can be significantly reduced through the use of chlorhexidine-impregnated transparent dressings as part of routine CVC maintenance.
Create your account
Always verify citation format against your institution’s current style guide requirements.